SPD 554
Alternative Names: Guanfacine Carrier Wave project; SPD-554Latest Information Update: 15 Jan 2019
Price :
$50 *
At a glance
- Originator Shire
- Class Anxiolytics
- Mechanism of Action Alpha 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anxiety disorders; Attention-deficit hyperactivity disorder; Autistic disorder
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 30 Jun 2013 Discontinued - Phase-I for Anxiety disorders (in children) in Ireland (unspecified route)
- 30 Jun 2013 Discontinued - Phase-I for Autistic disorder in Ireland (unspecified route)